Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.” Their mean rating for Vertex stock is 1.84, and their target price is $201.82, implying a 23.5% upside for the stock based on its December 18 closing price of $163.43.
Vertex’s current ratio, which shows how effectively it can meet its short-term obligations, is 3.70x. In comparison, Amgen’s, Biogen’s, and Pfizer’s current ratios are 3.10x, 2.70x, and 1.40x, respectively.
After rising from $147.50 on June 27 to a high of $192.74 on September 28, Vertex stock corrected to $159.76 on November 20. Initial buying interest then took it to $184.65 on December 3 before the stock corrected again. It currently stands at $163.40.
Vertex’s long-term debt-to-equity ratio is 0.20x, whereas Amgen, Biogen, and Pfizer have debt-to-equity ratios of 2.05x, 0.43x, and 0.47x, respectively.
In fiscal 2018 and fiscal 2019, Vertex’s free cash flow is expected to be $778.63 million and $1.12 billion, respectively, compared with $745.52 million in fiscal 2017. Its price-to-free-cash-flow ratio is 36.12x, while Amgen’s, Biogen’s, and Pfizer’s ratios are 17.65x, 10.41x, and 25.57x, respectively.